Bristol Myers Squibb Company $BMY Shares Bought by Pictet Asset Management Holding SA

Posted by Brenda Bartman on Nov 9th, 2026

Pictet Asset Management Holding SA raised its position in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 0.4% during the 3rd quarter, Holdings Channel reports. The firm owned 2,035,236 shares of the biopharmaceutical company’s stock after acquiring an additional 8,549 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Bristol Myers Squibb were worth $127,002,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. Leelyn Smith LLC lifted its holdings in shares of Bristol Myers Squibb by 0.8% in the third quarter. Leelyn Smith LLC now owns 59,776 shares of the biopharmaceutical company’s stock valued at $3,730,000 after purchasing an additional 464 shares in the last quarter. Pegasus Asset Management Inc. acquired a new stake in shares of Bristol Myers Squibb in the third quarter valued at approximately $225,000. May Hill Capital LLC increased its stake in shares of Bristol Myers Squibb by 13.3% during the 3rd quarter. May Hill Capital LLC now owns 4,296 shares of the biopharmaceutical company’s stock worth $268,000 after purchasing an additional 503 shares in the last quarter. Alps Advisors Inc. increased its stake in shares of Bristol Myers Squibb by 13.2% during the 3rd quarter. Alps Advisors Inc. now owns 632,070 shares of the biopharmaceutical company’s stock worth $39,441,000 after purchasing an additional 73,806 shares in the last quarter. Finally, Ashton Thomas Private Wealth LLC increased its stake in shares of Bristol Myers Squibb by 7.7% during the 3rd quarter. Ashton Thomas Private Wealth LLC now owns 131,709 shares of the biopharmaceutical company’s stock worth $8,219,000 after purchasing an additional 9,442 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Rothschild & Co Redburn boosted their price target on Bristol Myers Squibb from $51.00 to $53.00 and gave the stock a “neutral” rating in a report on Thursday, October 8th. Bank of America restated a “buy” rating on shares of Bristol Myers Squibb in a research report on Friday, October 30th. Zacks Research lowered Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 22nd. Morgan Stanley dropped their price objective on Bristol Myers Squibb from $41.00 to $40.00 and set an “underweight” rating for the company in a research report on Friday, October 30th. Finally, Truist Financial set a $70.00 target price on shares of Bristol Myers Squibb in a research note on Friday, October 30th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Bristol Myers Squibb presently has an average rating of “Hold” and a consensus target price of $65.46.

View Our Latest Stock Report on Bristol Myers Squibb

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

Positive Sentiment: Bristol Myers Squibb reported 56-week Phase 3 results for Camzyos (mavacamten) in children with symptomatic obstructive hypertrophic cardiomyopathy. Sustained efficacy could support the drug’s potential in a broader patient population, though the report does not say that pediatric use has been approved. Article: Bristol-Myers Squibb Says Camzyos Shows Sustained Efficacy in Phase 3 Pediatric Trial
Positive Sentiment: A multi-year AI alliance expands the company’s neuroscience efforts, potentially supporting future drug discovery, although the supplied report gives no financial terms or near-term revenue outlook. Article: Bristol Myers Squibb Expands Neuroscience Push With Multi Year AI Alliance
Positive Sentiment: Recent coverage also highlighted FDA accelerated approval for ZENBEXUS in multiple myeloma and positive trial updates in other diseases. These developments add to the pipeline narrative, though investors may weigh how much expected optimism is already reflected in the shares. Article: Bristol Myers Squibb Wins FDA Approval
Neutral Sentiment: A company director disclosed selling 3,800 shares. Insider sales can attract attention, but the filing alone does not establish the director’s reason or signal a change in the company’s outlook. SEC Form 4 filing
Negative Sentiment: A dividend-focused article flags potential pressure from an expected $1.5 billion–$2 billion decline in blood-thinner sales and the company’s debt burden. That raises questions about dividend sustainability, though the article does not establish that a cut is imminent. Article: Bristol Myers Squibb Yields Over 4%. Can Its Dividend Survive 2027?

Bristol Myers Squibb Price Performance

Bristol Myers Squibb stock opened at $62.20 on Monday. Bristol Myers Squibb Company has a 1 year low of $45.26 and a 1 year high of $68.64. The firm has a 50 day moving average price of $62.34 and a 200 day moving average price of $60.11. The company has a market cap of $127.15 billion, a price-to-earnings ratio of 13.79, a PEG ratio of 0.32 and a beta of 0.20. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.44 and a current ratio of 1.59.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share for the quarter, beating analysts’ consensus estimates of $1.10 by $0.25. The firm had revenue of $13.07 billion for the quarter, compared to analysts’ expectations of $12.72 billion. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. The firm’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same quarter last year, the firm earned $1.63 earnings per share. Sell-side analysts predict that Bristol Myers Squibb Company will post 6.45 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd were given a $0.63 dividend. The ex-dividend date of this dividend was Friday, October 2nd. This represents a $2.52 annualized dividend and a yield of 4.1%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 55.88%.

Insider Activity at Bristol Myers Squibb

In related news, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. This trade represents a 2.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Julia A. Haller sold 3,800 shares of the firm’s stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $63.31, for a total value of $240,578.00. Following the sale, the director owned 30,279 shares of the company’s stock, valued at $1,916,963.49. This represents a 11.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.05% of the stock is owned by company insiders.

Bristol Myers Squibb Company Profile

(Free Report)

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease.

The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

Bristol Myers Squibb was formed in 1989 through the merger of Bristol-Myers, founded in 1887, and the E.